PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11260405-10 2001 The high correlation between the renal hemodynamic response to captopril and to candesartan indicates that reduced angiotensin II formation is the main mechanism of action of the ACE inhibitor. candesartan 80-91 angiotensin I converting enzyme Homo sapiens 179-182 11059637-6 2000 Blockade of the AT1-receptor, with agents such as candesartan, produces more specific and, theoretically, more complete blockade of the major negative cardiovascular effects of angiotensin II than is possible using ACE inhibitors, whilst maintaining placebo-like tolerability. candesartan 50-61 angiotensin I converting enzyme Homo sapiens 215-218 11881058-7 2001 This remarkable response to candesartan in subjects on a high-salt diet,when compared with the response to captopril,suggests that non-ACE-dependent Ang II generation was influenced less than the classical renal pathway with an increase in salt intake, so that the percentage of Ang II generated via the non-ACE pathway rose to the 60-70% range. candesartan 28-39 angiotensin I converting enzyme Homo sapiens 135-138 28425795-8 2000 Candesartan, on the other hand, binds insurmountably to the AT 1 -receptor, thereby providing more complete blockade of the negative cardiovascular effects of angiotensin II than is possible with ACE inhibitors. candesartan 0-11 angiotensin I converting enzyme Homo sapiens 196-199 28425812-6 2000 Blockade of the AT1-receptor, with agents such as candesartan, produces more specific and, theoretically, more complete blockade of the major negative cardiovascular effects of angiotensin II than is possible using ACE inhibitors, whilst maintaining placebo-like tolerability. candesartan 50-61 angiotensin I converting enzyme Homo sapiens 215-218 11059629-8 2000 Candesartan, on the other hand, binds insurmountably to the AT1-receptor, thereby providing more complete blockade of the negative cardiovascular effects of angiotensin II than is possible with ACE inhibitors. candesartan 0-11 angiotensin I converting enzyme Homo sapiens 194-197 18366776-2 2008 We also wanted to examine whether a clinical response to an ACE inhibitor, lisinopril, or an angiotensin II receptor blocker, candesartan, in migraine prophylaxis was related to ACE genotype. candesartan 126-137 angiotensin I converting enzyme Homo sapiens 178-181 28905031-5 2016 Use an angiotensin II receptor blocker (ARB) (candesartan or valsartan) if intolerant to ACE inhibitors because of cough or angioneurotic edema. candesartan 46-57 angiotensin I converting enzyme Homo sapiens 89-92 27924184-8 2016 The reported adverse events among patients newly treated with an ACE inhibitor peaked in 2007 to 10 cases per 1000 patients, and gradually decreased to 4.6 cases in 2012, which was the year after the PA requirements for the ARBs valsartan and candesartan were rescinded by the HMO. candesartan 243-254 angiotensin I converting enzyme Homo sapiens 65-68 19436650-6 2009 The benefits of candesartan have been demonstrated by the CHARM programme, which showed that candesartan significantly reduces the incidence of cardiovascular death, hospital admissions for decompensated heart failure, and all-cause mortality in chronic heart failure patients with altered left ventricular systolic function, when added to standard therapies or as an alternative to ACE inhibitors when these are poorly tolerated. candesartan 16-27 angiotensin I converting enzyme Homo sapiens 383-386 19436650-6 2009 The benefits of candesartan have been demonstrated by the CHARM programme, which showed that candesartan significantly reduces the incidence of cardiovascular death, hospital admissions for decompensated heart failure, and all-cause mortality in chronic heart failure patients with altered left ventricular systolic function, when added to standard therapies or as an alternative to ACE inhibitors when these are poorly tolerated. candesartan 93-104 angiotensin I converting enzyme Homo sapiens 383-386 28587581-3 2017 METHODS: The ACE phenotype was determined in plasma of 14 patients with hypertension treated chronically for 4 weeks with 40 mg enalapril (E) or 20 mg E + 16 mg candesartan (EC) and in 20 patients with hypertension treated acutely with a single dose (20 mg) of E with or without pretreatment with hydrochlorothiazide. candesartan 161-172 angiotensin I converting enzyme Homo sapiens 13-16 20086184-14 2010 Low-dose lisinopril or candesartan may be reasonable second- or third-line agents, particularly in patients with other indications for ACE inhibitor or ARB therapy. candesartan 23-34 angiotensin I converting enzyme Homo sapiens 135-138 18594050-3 2008 OBJECTIVE: To explore the impact of selected candidate genes on the hemodynamic, neurohormonal, and antiinflammatory effects of candesartan in patients with heart failure who are already being treated with an ACE inhibitor. candesartan 128-139 angiotensin I converting enzyme Homo sapiens 209-212 18594050-4 2008 METHODS: We investigated the impact of 10 candidate genetic polymorphisms on the effects of candesartan in patients with heart failure who are treated with an ACE inhibitor. candesartan 92-103 angiotensin I converting enzyme Homo sapiens 159-162 18594050-10 2008 CONCLUSIONS: The results of this proof-of concept study provide the first evidence that the AGTR1 A1166C polymorphism could influence the response to candesartan in patients with heart failure who are receiving ACE inhibitors. candesartan 150-161 angiotensin I converting enzyme Homo sapiens 211-214 17824291-6 2007 Furthermore, a significant decrease of the total peripheral resistance was measured under eprosartan (23%; P = 0.002), telmisartan (18%; P = 0.002) and candesartan treatment (11.5%; P = 0.049); in the subgroup of combined therapy with beta blockers, ACE-inhibitors and ATI-antagonists a significant increase in cardiac output was also observed. candesartan 152-163 angiotensin I converting enzyme Homo sapiens 250-253 16601570-6 2006 RESULTS: In patients with intolerance to an ACE inhibitor and an LVEF of 40% or less (the CHARM-Alternative trial), candesartan reduced cardiovascular mortality and hospitalizations for heart failure by 23% (P < 0.001). candesartan 116-127 angiotensin I converting enzyme Homo sapiens 44-47 17395047-7 2007 CONCLUSIONS: The addition of candesartan to ACE inhibitor and beta-blocker decreases Nt-proBNP and hsCRP, but does not change the other markers of inflammation or oxidative stress in patients with heart failure. candesartan 29-40 angiotensin I converting enzyme Homo sapiens 44-47 17061457-3 2006 In the CHARM program, candesartan reduced by 20% the incidence of AF and thus also mortality and the incidence of hospitalisation for heart failure related to AF This beneficial effect is also observed with ACE inhibitors but is more important and potentated by ARB. candesartan 22-33 angiotensin I converting enzyme Homo sapiens 207-210 17699280-12 2006 In the patients who were treated with candesartan and ACE inhibitor or ACE inhibitor alone, pretreatment proteinuria correlated significantly with decline of renal function, whereas reduction of proteinuria negatively correlated with decline in renal function in the patients who were treated with candesartan. candesartan 298-309 angiotensin I converting enzyme Homo sapiens 54-57 17699280-12 2006 In the patients who were treated with candesartan and ACE inhibitor or ACE inhibitor alone, pretreatment proteinuria correlated significantly with decline of renal function, whereas reduction of proteinuria negatively correlated with decline in renal function in the patients who were treated with candesartan. candesartan 298-309 angiotensin I converting enzyme Homo sapiens 71-74 17699280-13 2006 Candesartan with an ACE inhibitor is effective in slowing the progression of renal insufficiency in hypertensive patients with nondiabetic renal disease through reduction of proteinuria. candesartan 0-11 angiotensin I converting enzyme Homo sapiens 20-23 17245479-3 2006 In CHARM-Alternative, candesartan significantly reduced the risk of cardiovascular death or hospitalization for heart failure in patients who could not tolerate angiotensin-converting enzyme (ACE) inhibitors. candesartan 22-33 angiotensin I converting enzyme Homo sapiens 161-190 17245479-4 2006 This risk was also significantly lowered by candesartan in CHARM-Added, which included patients who were already on ACE inhibitor therapy. candesartan 44-55 angiotensin I converting enzyme Homo sapiens 116-119 16644319-0 2006 Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. candesartan 94-105 angiotensin I converting enzyme Homo sapiens 35-64 16644319-0 2006 Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. candesartan 113-124 angiotensin I converting enzyme Homo sapiens 35-64 16644319-8 2006 The benefit of candesartan was preserved in patients taking beta-blockers in addition to a higher dose of ACE inhibitor and in patients maintaining a high dose of ACE inhibitor throughout follow-up. candesartan 15-26 angiotensin I converting enzyme Homo sapiens 106-109 16644319-8 2006 The benefit of candesartan was preserved in patients taking beta-blockers in addition to a higher dose of ACE inhibitor and in patients maintaining a high dose of ACE inhibitor throughout follow-up. candesartan 15-26 angiotensin I converting enzyme Homo sapiens 163-166 16601570-7 2006 In patients with an LVEF of 40% or less treated with an ACE inhibitor (the CHARM-Added trial), candesartan reduced cardiovascular death and hospitalization for chronic heart failure by 15% (P = 0.011). candesartan 95-106 angiotensin I converting enzyme Homo sapiens 56-59 15550793-6 2004 In patients with systolic dysfunction who are intolerant to ACE-Is, candesartan has been shown to reduce cardiovascular mortality and hospital admissions for heart failure. candesartan 68-79 angiotensin I converting enzyme Homo sapiens 60-63 15857354-7 2005 The CHARM programme showed that candesartan reduced morbidity and mortality in heart failure with reduced systolic function, both when added to ACE inhibitor therapy or when used as an alternative in patients who are intolerant to ACE inhibitors. candesartan 32-43 angiotensin I converting enzyme Homo sapiens 144-147 15857354-7 2005 The CHARM programme showed that candesartan reduced morbidity and mortality in heart failure with reduced systolic function, both when added to ACE inhibitor therapy or when used as an alternative in patients who are intolerant to ACE inhibitors. candesartan 32-43 angiotensin I converting enzyme Homo sapiens 231-234 16285075-6 2005 (5) In patients with heart failure who had stopped taking an ACE inhibitor because of adverse effects, candesartan had no effect on mortality as compared with placebo, but it did reduce the risk of clinical deterioration (3 fewer hospitalisations per year per 100 patients). candesartan 103-114 angiotensin I converting enzyme Homo sapiens 61-64 16285075-7 2005 However, candesartan was associated with adverse effects such as renal failure and hyperkalemia, especially in patients who had experienced these same adverse effects while taking an ACE inhibitor. candesartan 9-20 angiotensin I converting enzyme Homo sapiens 183-186 16028461-8 2005 The Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program demonstrated significant reductions in morbidity and mortality with the ARB candesartan in patients with HF due to systolic dysfunction, with or without ACE inhibitors and with or without beta blockers. candesartan 4-15 angiotensin I converting enzyme Homo sapiens 253-256 15384026-11 2004 CONCLUSION: In ESRD patients on CAPD, the standard dose of ACE inhibitor, enalapril, or ARB, candesartan,has little effect on serum potassium, despite drops of plasma aldosterone observed. candesartan 93-104 angiotensin I converting enzyme Homo sapiens 59-62 15492298-11 2004 CONCLUSIONS: Candesartan significantly reduces all-cause mortality, cardiovascular death, and heart failure hospitalizations in patients with CHF and LVEF < or =40% when added to standard therapies including ACE inhibitors, beta-blockers, and an aldosterone antagonist. candesartan 13-24 angiotensin I converting enzyme Homo sapiens 211-214 15184734-4 2004 Candesartan was by and large well tolerated in these ACE-inhibitor intolerant patients; thus, the findings of this study provide additional support for the effectiveness of angiotensin receptor blocker therapy in heart failure patients poorly tolerant of an ACE inhibitor; however, candesartan was not convincingly shown to improve the incidence/severity of hypotension, hyperkalemia, and glomerular filtration rate reductions that were the basis for ACE inhibitor intolerance in approximately 25% of the study population. candesartan 0-11 angiotensin I converting enzyme Homo sapiens 53-56 13678869-12 2003 INTERPRETATION: The addition of candesartan to ACE inhibitor and other treatment leads to a further clinically important reduction in relevant cardiovascular events in patients with CHF and reduced left-ventricular ejection fraction. candesartan 32-43 angiotensin I converting enzyme Homo sapiens 47-50 14586718-1 2003 BACKGROUND: We previously reported that the angiotensin II type 1 receptor antagonist candesartan was effective in reducing blood pressure and microalbuminuria in hypertensive patients with diabetic nephropathy after angiotensin-converting enzyme (ACE) inhibitors were replaced due to side effects. candesartan 86-97 angiotensin I converting enzyme Homo sapiens 248-251 11917051-2 2002 The objectives of this study were to determine whether the addition of Candesartan, an angiotensin II receptor antagonist, would reduce proteinuria and blood pressure in normotensive patients with chronic renal disease already receiving an angiotensin converting enzyme inhibitor (ACEI). candesartan 71-82 angiotensin I converting enzyme Homo sapiens 240-269 12458654-1 2002 OBJECTIVE: To evaluate the efficacy and safety of candesartan in patients previously treated with, but displaying adverse reactions to, ACE inhibitors, beta-blockers, calcium antagonists or thiazide diuretics. candesartan 50-61 angiotensin I converting enzyme Homo sapiens 136-139 15449762-1 2004 The large Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial recently found that in patients with heart failure who were similar to those whom clinicians see in everyday practice, the angiotensin-receptor blocker candesartan was not only an acceptable alternative to angiotensin-converting enzyme (ACE) inhibitors, but also was beneficial when added to regimens that already included ACE inhibitors and beta-blockers. candesartan 256-267 angiotensin I converting enzyme Homo sapiens 310-339 15449762-1 2004 The large Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial recently found that in patients with heart failure who were similar to those whom clinicians see in everyday practice, the angiotensin-receptor blocker candesartan was not only an acceptable alternative to angiotensin-converting enzyme (ACE) inhibitors, but also was beneficial when added to regimens that already included ACE inhibitors and beta-blockers. candesartan 256-267 angiotensin I converting enzyme Homo sapiens 341-344 15449762-1 2004 The large Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial recently found that in patients with heart failure who were similar to those whom clinicians see in everyday practice, the angiotensin-receptor blocker candesartan was not only an acceptable alternative to angiotensin-converting enzyme (ACE) inhibitors, but also was beneficial when added to regimens that already included ACE inhibitors and beta-blockers. candesartan 256-267 angiotensin I converting enzyme Homo sapiens 427-430 15257162-8 2004 However, when compared with placebo, ACE inhibition by ramipril or by the ARB, candesartan, both decrease the incidence of new diabetes, raising the hypothesis that these agents actually prevent the changes leading to insulin resistance, possibly by lessening the adverse effects of angiotensin II on the endothelium. candesartan 79-90 angiotensin I converting enzyme Homo sapiens 37-40 14764285-0 2004 Candesartan reduces cardiovascular death in CHF patients on ACE inhibitor. candesartan 0-11 angiotensin I converting enzyme Homo sapiens 60-63 13678870-3 2003 We aimed to find out whether candesartan, an angiotensin-receptor blocker, could improve outcome in such patients not taking an ACE inhibitor. candesartan 29-40 angiotensin I converting enzyme Homo sapiens 128-131 13678870-12 2003 INTERPRETATION: Candesartan was generally well tolerated and reduced cardiovascular mortality and morbidity in patients with symptomatic chronic heart failure and intolerance to ACE inhibitors. candesartan 16-27 angiotensin I converting enzyme Homo sapiens 178-181 12222554-6 2002 While taking candesartan for hypertension, a 53-year-old woman with known ACE inhibitor intolerance developed angioedema. candesartan 13-24 angiotensin I converting enzyme Homo sapiens 74-77 12140730-4 2002 Activation of the renin-angiotensin system is increased in diabetic patients, and comparison of the renal vascular responses to captopril and candesartan shows a strong correlation between the effects of ACE inhibition and AT(1)-receptor blockade, indicating that the deleterious effects of renin-angiotensin system activation in diabetes are mediated largely through angiotensin II. candesartan 142-153 angiotensin I converting enzyme Homo sapiens 204-207 11457745-4 2001 The candesartan group included 5 subjects with a history of ACE inhibitor-induced cough. candesartan 4-15 angiotensin I converting enzyme Homo sapiens 60-63